FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,498,000 | -36.1% | 181,500 | 0.0% | 4.10% | -21.4% |
| Q1 2022 | $7,037,000 | -55.5% | 181,500 | -32.8% | 5.22% | -5.5% |
| Q4 2021 | $15,798,000 | -1.3% | 270,000 | 0.0% | 5.52% | +17.3% |
| Q3 2021 | $16,003,000 | -31.7% | 270,000 | 0.0% | 4.70% | -19.2% |
| Q2 2021 | $23,433,000 | +5.3% | 270,000 | 0.0% | 5.82% | +36.4% |
| Q1 2021 | $22,262,000 | -5.8% | 270,000 | +3.8% | 4.27% | +5.3% |
| Q4 2020 | $23,642,000 | – | 260,000 | – | 4.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |